current algorithm is based on data that has shown sentinel lymph node to be highly prognostic and an accurate staging test, with cited false negative rates for SLNB as low as 0-2%. 1 CLND has been shown to achieve optimal regional disease control. 2, 3 Patients undergoing CLND have a 10% nodal recurrence rate as opposed to patients with positive SLNB who did not undergo CLND that had a 15% incidence of nodal recurrence at the original site of dissection. 4, 5 Despite these recognized benefits, the usage of CLND has hovered historically at 50%. 6 Some have questioned the need to perform CLND for patients with a positive SLN, citing lack of evidence of disease-specific survival benefit and the risk of increased morbidity and cost incurred by the patient. 1, 5, 7 About 80% of patients with a positive SLNB will have no further detection of additional nodal disease by CLND, and these patients may receive no oncologic benefit from a procedure associated with high complication rates. 8 Attempts have been made to risk-stratify patients with positive SLNB based on primary tumor and sentinel node(s) tumor burden characteristics, but reliable determination of non-sentinel node disease is still elusive. 9, 10 To address this incomplete understanding of CLND utility, the Multicenter Selective Lymphadenectomy Trial II (MSLT-II) study was designed to determine whether at-risk melanoma patients derive survival benefit from CLND after a positive SLNB. This data will be critical in helping patients and clinicians weigh the benefits and risk of CLND. Until MSLT-II results become available, CLND should be considered standard of care and the decision to forego CLND should be based on factors such as patient comorbidities, preference and risk tolerance. 3, 11, 12 Though CLND was considered the standard of care prior to the ASCO/SSO guideline, a 50% rate of CLND following a positive SLNB points to nonadherence that was present before 2012. Due to the increasing incidence of melanoma and continued widespread lack of access and non-adherence to recommended oncologic care, the patient characteristics associated with undergoing and forgoing CLND after a positive SLNB deserve further study. 6, 13 This study aims to determine if certain patient factors were significant in this determination. We queried the American College of Surgeons National Cancer Data Base (NCDB) to determine trends in CLND over time, and whether certain patient-specific factors impact the likelihood of CLND.
2 | METHODS
| Data acquisition and study population
The NCDB is a program of the American College of Surgeons, the Commission on Cancer (CoC), and the American Cancer Society, and contains information on over 21 million patients. 14 Access to the melanoma participant user file (PUF) was secured through an application process, allowing delivery of de-identified patient-level data that does not identify hospitals, health care providers or patients. 15 Following appropriate Institutional Review Board approval from the University of Cincinnati, we identified all patients with invasive melanoma, of all stages and treatment type.
The melanoma PUF was queried for patients with pathologic stage I-III melanoma undergoing wide local excision (WLE), with or without SLNB, with or without CLND using PUF variables "TNM_PATH_STA-GE_GROUP," "REGIONAL_NODES_EXAMINED," "REGIONAL_NO-DES_POSITIVE," "DX_DEFSURG_STARTED_DAYS" respectively. 16 Patients with clinically positive nodes were excluded from this study. confidence intervals were generated, with a level of statistical significance set to P < 0.05.
Nominal categorical variables were tested for significance using
Pearson's chi-square test.
Ordinal categorical variables were similarly tested using the Mantel-Haenszel chi-squared test. Differences between CLND and SLNB groups were analyzed using the log-rank test. Univariate and multivariate analysis was performed using logistic regression to identify predictors of CLND and SLNB. Random intercept hierarchical models were used in all analyses to account for the clustering effects of the center where the patients underwent their surgery. All statistical analyses were performed using JMP Pro 11 and SAS 9.4 (SAS Institute, Cary, NC).
3 | RESULTS
| Predictors of completion lymph node dissection
Demographics and treatment classifications of the overall study population from 2003 to 2012 are shown in Table 1 . In total, 122 849 patients were identified who underwent WLE with SLNB. 19.8%
patients had a positive SLNB with 56.0% continuing to CLND overall; Table 1 shows these data separated by study era. Notably, in Era 1,
19.2% of 56 129 patients had a positive SLNB with 55.0% continuing to CLND. In Era 2, 20.3% of 66 720 were positive with 56.8%
continuing to CLND. Therefore, the difference in CLND rates between the two eras was +1.8%. Rates of change in CLND usage between eras for patient subsets (Table 2) were also compared using +1.8% as the standard increase in CLND utilization over time. Subsequently, multivariate analysis demonstrated that a patient's race, insurance status and lesion location were found to be associated with significantly decreased odds of undergoing CLND. Black patients (when compared to white patients) and patients with either head/neck or lower extremity lesions (when compared to trunk lesions) were found, in both eras, to be less likely to undergo CLND. Patients with either Medicaid or Medicare were found to be significantly associated with a lower rate of CLND utilization in Era 1. In Era 2, uninsured patients were less likely to undergo CLND
| Increasing and decreasing utilization of CLND
We then investigated trends in CLND utilization throughout our study period to elucidate any patient-specific features contributing to CLND rates over time. First, we identified factors associated with a relative decrease in use of CLND throughout the study periods (defined as patients with persistently low CLND utilization, characterized by Multivariate analysis conducted on patient characteristics to find associated odds ratios and confidence intervals with significance. Blacks, Medicaid, Medicare, head/neck lesions, lower extremity lesions and overlapping skin lesions were significant predictors of less CLND after positive SLNB. NOS, not otherwise specified; OR, odds ratio; LCL, lower confidence limit; UCL, upper confidence limit FIGURE 2 Forest plot of patient predictors of CLND from 2008 to 12. Blacks, no insurance, head/neck lesions, lower extremity lesions and overlapping skin lesions were significant predictors of less CLND after positive SLNB. Similar analyses were run for univariate analyses and multivariate analyses for Era 2. NOS, not otherwise specified; OR, odds ratio; LCL, lower confidence limit; UCL, upper confidence limit comparatively lower CLND rates by era and <1.8% growth in usage between eras). The first group-patients with persistently low CLND rates that did not increase at the same rates as the overall cohort-consisted of patients with lower median income (<$30 000
and $30,000-34 999), no insurance and head/neck lesions (Tables 1   and 2 ).
Conversely, a second subset analysis sought to identify predictors of increased CLND utilization (defined as >1.8% growth in CLND usage between the two eras), though at lower rates than the average overall patient population. This group consisted of 60-90-year-old patients, males, Black patients, those of lower education, Medicaid/Medicare, and lower extremity lesions. Though Black patients had the greatest growth in CLND utilization, they still demonstrated CLND rates far lower than both era average CLND rates.
Finally, we mention some predictors of increased CLND utilization (>1.8% growth) that received CLND at or above the average overall CLND rate (55.0% in Era 1 and 56.8% in Era 2). This group consisted of 40-59 year old patients, females, Asian patients, patients of the highest income bracket (>$46 000), those of higher education, upper extremity and trunk lesions. This group were not further analyzed for significance as they did not represent a disparity in receiving CLND. In this study, racial and socioeconomic differences in CLND rates were most dramatic, confirming previous reports that poorer, minority populations continue to be relative under-utilizers of CLND. 18 While all other patient cohorts in our study had CLND rates of at least 55%, Black patients underwent CLND only 41% of the time from 2008 to 12.
One reason for this may be disease presentation as it is welldocumented that Black patients present with higher severity of disease compared to white patients. [19] [20] [21] Further complicating the treatment of melanoma in Black patients, previous research has shown that among patients treated with surgery, 10-year melanoma-specific survival was lower in Blacks (73%) than in whites (88%). 22 The differences in disease presentation and course of treatment in Black patients contribute to disparities in survival, and special attention to melanoma in minority populations may lead to early detection and ultimately save lives. 20 Patient insurance status is another important factor in CLND.
Previous data suggest that approximately 1 in 5 Medicare beneficiaries experience some sort of delay in surgery for melanoma. 23 In our study, the Medicare cohort was found to have significantly decreased odds of CLND in the 2003-07 era and continued to receive CLND at a decreased but statistically insignificant rate at the end of our study.
As more citizens become eligible for government-issued Medicare as the incidence of melanoma increases, this patient population is at particular risk of non-adherence to recommended care. 24 Additionally, patients with no insurance demonstrated the only decrease in CLND rates over the entire study period compared to all insurancespecific cohorts. This trend clearly indicates a growing disparity in patients without insurance, which needs to be addressed at the policy level.
This study is not able to explain the disparities observed in melanoma treatment, but does identify patient characteristics associated with CLND after a positive SLNB. To better understand underlying drivers of the disparities and trends we have described, focus groups and/or patient interviews would be useful qualitative measures to strengthen our findings. Likely, prospective engagement of patients at-risk of not undergoing CLND will be required for impactful interventions to increase CLND utilization.
Currently, data suggest that there is no significant benefit to disease-specific survival from CLND, 1, 5, 7, 8 though reduction in locoregional recurrence is clear. 3, 4 The results of the MSLT-II trial may demonstrate that CLND has no associated survival benefit, and just as in breast cancer, may be discouraged as a routine recommendation for patients with positive sentinel lymph nodes. 25 Such a scenario would highlight the ongoing need to critically evaluate our surgical practices in an evidence-based fashion; the significant number of patients who will have undergone CLND unnecessarily will be of important historical significance. However, if a survival benefit of CLND is shown, our data should serve as a contemporary reference on which to guide future access and population health improvement initiatives. The utilization of CLND need to increase uniformly, and the disparities identified in this study must be addressed to minimize socioeconomic, racial and diseasespecific disparities.
Some limitations merit discussion. CLND is not performed for clinically-positive nodes and these patients were assumed to not have received SLNB or CLND. The retrospective design and use of registry data with its attendant selection bias does not allow for identification of causality. Furthermore, the overall NCDB case capture has been shown to be 67.4%, with coverage varying widely by site; melanoma capture by the NCDB is the lowest at 50.6%. 26 Confounding variables surrounding a patient's socioeconomic status such as race, education, insurance, or facility type may exist. For example, Black patients often get acral lentiginous melanoma which may be more aggressive and advanced at diagnosis, thereby impacting the decision for CLND. 27 While CLND has been considered the "standard of care" since the advent of sentinel lymph node biopsy, the recommendation for CLND after positive SLNB was updated in 2012 by ASCO and SSO, 1 at the conclusion of our study period. Thus a link between professional society recommendation and our findings cannot be made, though CLND was still considered an appropriate treatment course for a positive node before 2012. 28 Lastly, melanoma data captured by the NCDB do not include reasons why a patient did or did not receive CLND; these data will be necessary for addressing the disparities identified in this study.
In conclusion, we have shown that CLND following positive SLNB in melanoma continues to be performed at lower than recommended rates. Almost 50% of eligible patients are not undergoing CLND, and despite a marginal 1.8% improvement in CLND utilization over the last decade, significant disparities exist in CLND use. If the MLST-II trial demonstrates a significant survival benefit to CLND, these disparities require individual and policy-level attention from the melanoma community, as a means of substantially improving the outcomes for patients afflicted with this challenging disease.
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